Mivelsiran - Alnylam Pharmaceuticals
Alternative Names: ALN-APPLatest Information Update: 09 May 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Class Antidementias; Small interfering RNA
- Mechanism of Action Amyloid beta protein precursor expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cerebral amyloid angiopathy
- Phase I Alzheimer's disease
Most Recent Events
- 02 May 2024 Phase-II clinical trials in Cerebral amyloid angiopathy (Intrathecal)
- 02 May 2024 Alnylam Pharmaceuticals plans a phase-II trial for Cerebral amyloid angiopathy in mid-2024 (Intrathecal)
- 25 Oct 2023 Pharmacodynamics data from phase I trial in Alzheimer's disease released by Alnylam Pharmaceuticals